A

ALIGN TECHNOLOGY INC

ALGN Nasdaq Healthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies Tempe, AZ www.aligntech.com
$171.16
Mkt Cap 12.26B
Align Technology, Inc. ( we, us, our, Align or the Company ) is a global medical device company primarily engaged in the design, manufacture and marketing of Invisalign clear aligners for the treatmen…

Align Technology, Inc. ( we, us, our, Align or the Company ) is a global medical device company primarily engaged in the design, manufacture and marketing of Invisalign clear aligners for the treatment of malocclusions, or the misalignment of teeth, by orthodontists and general dental practitioners ( GPs ), Vivera TM retainers for retention, iTero TM intraoral scanners and services for dentistry, and exocad TM computer-aided design and computer-aided manufacturing ( CAD/CAM ) software for dental laboratories and dental practitioners. Our vision and strategy is to revolutionize orthodontic and restorative dentistry through digital treatment planning and implementation using the Align TM Digital Platform, an integrated suite of proprietary technologies and services designed to deliver a seamless, end-to-end solution for patients, consumers, orthodontists, GPs and lab partners. We strive to achieve our vision and strategy through key objectives made possible with the proprietary technologies and services of the Align TM Digital Platform to establish: clear aligners as the principal solution for the treatment of malocclusions with the Invisalign System as the treatment solution of choice by orthodontists, GPs and patients 3 globally, our iTero intraoral scanners as the preferred scanning technology for digital dental scans and our exocad CAD/CAM software as the dental restorative solution of choice for dental labs. Our corporate headquarters are located at 410 North Scottsdale Road, Suite 1300, Tempe, Arizona 85288. Our telephone number is 602-742-2000.

/100 Overall
Calculating score…
Running full analysis
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$4.14B
FCF TTM
$302.7M
P/E RATIO
29.6x
P/FCF
40.5x
Running full 6-factor analysis…